mobile nav toggler

investors

Provention Bio, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases. Our mission is to in-license, transform and develop clinical-stage, or nearly clinical-stage, therapeutic candidates targeting the high morbidity, mortality and escalating costs of autoimmune and inflammatory diseases.

recent releases
Nov 8, 2018

Q3 2018 and Recent Corporate Highlights: Completed $63.9 million upsized initial public offering Announced co-development agreement with Amgen and in-licensing of PRV-015 (Amgen's AMG-714), a...

Nov 5, 2018

THOUSAND OAKS, Calif. and OLDWICK, N.J. – (Nov. 5, 2018) – Amgen (NASDAQ:AMGN) and Provention Bio, Inc. (NASDAQ:PRVB), a clinical-stage biopharmaceutical company focused on immune-mediated...

Nov 1, 2018

Provention Bio, Inc. (Nasdaq:PRVB), a clinical-stage biopharmaceutical company focused on preventing and intercepting immune-mediated diseases, announced today it will host a conference call and...

View All Releases >

current stock price
NASDAQPRVB
NASDAQPRVB

investor relations contact

For more information contact Joshua Drumm, Ph.D., Tiberend Strategic Advisors, Inc.
212.375.2664 

email Joshua

Sign Up For Email Alerts